SCH-451659
| Code | Size | Price |
|---|
| TAR-T28727-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
SCH-451659 is an 17β-hydroxysteroid dehydrogenases (17β-HSDs) inhibitor.
CAS:
502628-66-2
Formula:
C30H39Cl2N3O2
Molecular Weight:
544.56
Purity:
0.98
SMILES:
CC(=O)N1CCC(CC(=O)N2CCN(C[C@@H]2C(C)(C)C)C(c2ccc(Cl)cc2)c2ccc(Cl)cc2)CC1
References
1. Day JM, Foster PA, Tutill HJ, Schmidlin F, Sharland CM, Hargrave JD, Vicker N, Potter BV, Reed MJ, Purohit A. STX2171, a 17?-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocr Relat Cancer. 2013 Feb 18;20(1):53-64. doi: 10.1530/ERC-12-0231. Print 2013 Feb. PubMed PMID: 23132791.